Ackman's $400M brain institute is a bet that universities have lost the recruiting war

Bill Ackman and Neri Oxman said on August 19 that they are donating roughly $400 million in Pershing Square stock to anchor a new Manhattan neuroscience and longevity center, the Ackman Oxman Institute, with a second gift of similar or potentially greater size to follow ^[1]. The interesting part is not the number but the stated reason for the timing: Ackman wrote that five years ago the couple shelved the same idea because it would have been "too difficult to recruit the best talent from universities," and that the equation has since changed ^[2].

His explanation for the change is two-sided. On the cost side, the real estate came available at a 70% discount ^[3]. On the labour side, he wrote that universities have become "a much less attractive place to work," citing campus politics, antisemitism and declining funding ^[4]. Ackman offered no data on researchers leaving universities en masse, according to Fortune's account of the post ^[5]. That is worth holding onto, because the institute's entire staffing plan rests on the proposition that top scientists can now be persuaded to leave, or at least to work outside, the university system ^[6]. It also sits inside a longer campaign: Ackman helped lead the pressure that preceded Harvard president Claudine Gay's departure, attacked the university's handling of antisemitism and its DEI policies, and later called for board members to be removed ^[7].

The physical build is already further along than the thesis. The Pershing Square Foundation bought a nearly vacant 400,000-square-foot biotech facility on Manhattan's West Side after a real estate contact flagged it in May, has an adjoining 130,000-square-foot building under contract, and is acquiring a neighbouring vacant lot ^[8]. That is 530,000 square feet secured or committed ^[9]. Ackman said current zoning would allow the campus to reach 680,000 square feet, larger than Rockefeller University's laboratory footprint ^[10] - roughly another 150,000 square feet of construction on top of what is in hand ^[11].

The operating model is the sharper break with academia. AOI is a nonprofit that Ackman says will have "highly commercial instincts": its own venture funding arm, companies created and seeded around in-house technology, and returns recycled into research ^[12]. He was explicit that it will not be an academic institute producing "lots of papers" with "little if any results for patients," and that the mandate is speed from bench to treatments and devices ^[13]. Mount Sinai is named as an important partner but not the only collaborator, on the stated view that no institution has a monopoly on ideas or talent ^[14]. The origin story is family: Oxman's mother died of Alzheimer's, and the couple's 26-year-old daughter Lucy suffered a brain hemorrhage and emergency surgery after being found unconscious in her Brooklyn apartment ^[15][16]. Ackman has said he pushed her doctors toward novel treatments, including injecting mitochondria into her eye to preserve her sight ^[17].

Two things to watch. First, the funding instrument: an endowment denominated in Pershing Square stock ^[1] carries the sponsor's own performance risk, so the institute's spending capacity is a function of one manager's fortunes rather than a diversified portfolio. Second, recruitment disclosures. The talent thesis is testable within a year or two - named hires, and where they came from, will show whether the balance of power Ackman describes actually exists, or whether $400 million plus discounted lab space is simply enough to buy scientists out of any employer.